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It is known that the metabolic syndrome has a multi-factorial basis involving both genetic and environmental risk factors. In this
study, Tsumura Suzuki Obese Diabetes (TSOD) mice, a mouse model of multi-factorial, hereditary, obese type II diabetes, were
givenaWesterndiet(WTD)asanenvironmentalfactortoprepareadiseasemodel(TSOD-WTD)andtoinvestigatethepreventive
eﬀects of Pine bark extract (Flavangenol) against obesity and various features of metabolic disease appearing in this animal model.
In contrast to control Tsumura Suzuki Non-obesity (TSNO) mice, TSOD mice were obese and suﬀered from other metabolic
complications. WTD-fed TSOD mice developed additional features such as hyperinsulinemia, abnormal glucose/lipid metabolism
andfattyliver.ThetreatmentwithFlavangenolhadasuppressiveeﬀectonincreaseinbodyweightandaccumulationofvisceraland
subcutaneousfat,andalsoshowedpreventiveeﬀectsonsymptomsrelatedtoinsulinresistance,abnormalglucose/lipidmetabolism
and hypertension. Flavangenol also increased the plasma concentration of adiponectin and decreased the plasma concentration of
TNF-α. We next investigated the eﬀect of Flavangenol on absorption of meal-derived lipids. Flavangenol suppressed absorption
of neutral fat in an olive-oil-loading test (in vivo) and showed an inhibitory eﬀect on pancreatic lipase (in vitro). The above
results suggest that Flavangenol has a preventive eﬀect on severe metabolic disease due to multiple causes that involve both genetic
and environmental risk factors. The mechanism of action might involve a partial suppressive eﬀect of meal-derived lipids on
absorption.
1.Introduction
Obesity, especially accumulation of visceral fat, is associated
with a potential for harm and provides a pathological
basis for various metabolic diseases, the development of
diabetes/abnormal lipid metabolism/hypertension and other
metabolic complications starting with insulin resistance and
progressing to arteriosclerosis and ischemic cerebral/cardiac
diseases. Prioritized exploratory research has sought materi-
als for developing drugs to prevent and treat these disorders.
Pine bark extract (Flavangenol), obtained from the
pine trees that grow on the west coast of France (Pinus
maritima),containsoligomericproanthocyanidincomplexes
(catechin oligomers) as the major ingredient. Pine bark
extract is reported to be an antioxidant [1]a n da n t i -
inﬂammant [2], with the capacity to improve diabetic
microvascular damage [3], vascular endothelial cell function
[4–6] and ischemia/reperfusion-induced renal injury [7].
Clinical studies indicate that the extract is eﬀective in the
treatment of chronic venous insuﬃciency and retinal micro-
hemorrhages [8].
The primary causes of obesity and metabolic dis-
eases based on obesity include genetic factors [9–11]a n d2 Evidence-Based Complementary and Alternative Medicine
environmental factors (overeating, stress, development of
means of transportation). We previously developed an
animalmodelofthedisease,TsumuraSuzukiObeseDiabetes
(TSOD), which spontaneously develops various features
similar to those of human metabolic diseases, and conﬁrmed
that this is a spontaneous obese mouse model of type II
diabetes [12–14]. In addition, Izumi et al. analyzed TSOD
mice by the QTL mapping method and reported that this is
a multi-factorial hereditary obesity/metabolic disease model
with mutations in the gene loci controlling body weight,
insulin level, fat level and adipocyte size [15, 16].
In this study, TSOD mice with genes for metabolic dis-
ease were given a Western diet (WTD) as an environmental
factor, and the preventive eﬀects of Flavangenol on various
metabolic disease features were investigated. Furthermore,
to clarify the mechanism of action of Flavangenol, we
investigated the eﬀect of Flavangenol on absorption of meal-
derived lipids.
2. Methods
2.1. Experimental Materials. Flavangenol used in this study
was supplied by Toyo Shinyaku Co. Ltd (Saga Prefecture),
and contains 72.5% polyphenol (determined by the Folin-
Denis method) including 5% proanthocyanidin B1, 2.98%
catechin and 0.23% epicatechin.
The WTD, F2WDT (Oriental Yeast Co., Ltd, Tokyo),
contains 19.82% casein, 0.3% l-cystine, 3.7458% cornstarch,
1.25% α-Cornstarch, 34% sucrose, 1.0% soybean oil, 5.0%
cellulose powder, 1.0% AIN-93 vitamin mixture, 3.5 AIN-
93G mineral mixture, 0.25% choline bitratrate, 0.0042%
t-butylhydroquinone, 20.0% milk fat (butter, etc.), 9.98%
maltodextrin and 0.15% cholesterol. The total calories of
nutritional elements were 450.8kcal/100g, and the calorie
percentages were 17.8% for protein, 20.0% for lipid and
49.0% for carbohydrate. As a control diet, MF (Oriental
Yeast Co. Ltd) was used as an “ordinary diet” (total calorie
of nutritional elements: 360kcal/100g, calorie percentages:
23.6%forprotein,5.3%forlipidand6.1%forcarbohydrate).
2.2. Experimental Animals. TSOD mice and the corre-
sponding control Tsumura Suzuki Non-Obesity (TSNO)
mice (derived from the same ancestry but developing no
metabolic disease), were purchased from the Institute for
Animal Reproduction (Ibaraki Prefecture) at the age of
3 weeks. On the other hand, 5-week-old ddY mice were
purchased from Tokyo Laboratory Animals Science Co. Ltd
(Tokyo). The mice were acclimated for one week to the
temperature of 23 ± 2◦C and humidity of 55 ± 10%,
and were given an ordinary MF powder diet and puriﬁed
water ad libitum. After the acclimation, TSOD and TSNO
mice were weighed and assigned to ﬁve groups (the TSNO-
MF group: TSNO mice given MF; the TSOD-MF group:
TSOD mice given MF; the TSOD-WTD group: TSOD mice
given WTD; the TSOD-WTD-Flavangenol 3% group: TSOD
mice given the WTD containing 3% Flavangenol; and the
TSOD-WTD-Flavangenol 5% group: TSOD mice given the
WTD containing 5% Flavangenol), ensuring that the body
weight was distributed uniformly. Flavangenol was mixed
well with the WTD so that the content was uniformly 3
or 5%. During the 8-week experiment, each group was
given water and each deﬁned diet ad libitum. All the animal
experiment procedures were performed pursuant to the
Animal Experiment Ethical Rules of Musashino University.
2.3. Components Examined During the Animal Experiment.
All the animals were weighed once a week, and the food
intakewasdeterminedeveryotherweek[17–20].Forinvesti-
gating the time-course of changes in amounts of visceral and
subcutaneous fat, the amounts of visceral and subcutaneous
fat were determined at the start of the experiment and at
following 4 and 8 weeks, a total of three times, by X-ray
computed tomography (CT; Latheta, Aloka Co. Ltd. Tokyo)
with scanning from the ensiform process to the sacral bone
at distance intervals of 1.5mm under anesthetization with
Nembutal (50 mg/kg i.p.).
2.4. Glucose-Loading Test and Blood Pressure Determination.
The glucose-loading test and blood pressure determination
were performed 8 weeks after the start of the experiment.
In the glucose-loading test, each mouse after fasting for
one night was given oral glucose (2g/kg); blood sampling
from the orbital venous plexus was performed at the deﬁned
time points under non-anesthetized conditions. The plasma
samples obtained by centrifugation were stored at –80◦C
until determination of glucose concentrations.
The blood pressure was determined with a non-invasive
blood pressure meter (Softron Co. Ltd, Tokyo) by ﬁxing each
mouse in a ﬁxing apparatus (Softron Co. Ltd) under non-
anesthetized conditions. The cuﬀ was set at the tail root to
determine the systolic/diastolic/mean blood pressures.
2.5. Components Examined at the End of the Experiment.
Under non-fasting conditions, each mouse was anesthetized
with ether and the blood was drawn from the abdominal
vena cava. The plasma samples obtained by centrifugation
were stored at –80◦C until blood biochemical tests could be
performed. At the time of autopsy, the liver, mesenteric fat,
perinephric fat, epididymal fat and retroperitoneal fat were
isolated and weighed. Using the plasma samples obtained,
the glucose, total cholesterol, triacylglycerol and free fatty
acid levels were determined with biochemical tests kits
obtained from Wako Pure Chemical Industries Ltd (Tokyo).
The insulin level was determined with Rebis Insulin-Mouse-
T (Shibayagi Co. Ltd, Gunma Prefecture), the adiponectin
level with Mouse Adiponectin/Acrp30 Immunoassay (R&D
Systems)andtheTNF-αlevelwithTNF-αELISA(BioCosmo
C o .L t d ,T o k y o ) .
2.6. Olive-Oil-Loading Test and Pancreatic Lipase Inhibition
Test. The olive-oil-loading test was performed according
to the method of Ninomiya et al. [21]. After fasting for
one night, 6-week-old ddY mice were orally administered
with Flavangenol (0.5 or 1g/kg), and 30min later, with
olive oil (5mL/kg). Blood sampling from the orbital venous
plexus was performed at the deﬁned time points under non-
anesthetized conditions. The plasma samples obtained byEvidence-Based Complementary and Alternative Medicine 3
centrifugation were stored at −80◦C until determination of
triacylglycerol concentrations.
The pancreatic lipase inhibition test was performed
according to the method of Ninomiya et al. [21], using a
general kit (Lipase Kit S: Dainippon Sumitomo Pharma Co.
Ltd, Osaka) and porcine pancreatic lipase (L3126 Type II,
Sigma-Aldrich, St Louis, MO).
2.7. Statistical Analysis. The data were displayed as mean ±
standarddeviation(SD).Ineachexperiment,theinter-group
diﬀerence was tested for signiﬁcance by Dunnett’s multiple
comparison procedure with a signiﬁcance level of 0.05.
3. Results
3.1. Changes in Body Weight and Food Intake. The body
weight in the TSOD-MF group was signiﬁcantly higher than
in TSNO-MF group as the control group, and it became
even greater in the TSOD-WTD group fed with the WTD. In
the TSOD-WTD-Flavangenol groups, a dose-dependent and
signiﬁcant suppressant eﬀect was seen on body weight from
the ﬁrst week after the start of the experiment, as compared
with the TSOD-WTD group, and body weight lower than in
the TSOD-MF group was seen from 4 weeks after the start
of the experiment (Figure 1). Table 1 shows the food and
energy intake in each group at 8 weeks after the start of the
experiment. The food and energy intake in the TSOD-MF
groupweresigniﬁcantlyhigherthanintheTSNO-MFgroup,
showing thatTSOD mice overeatand ingest excessive energy.
The food intake was signiﬁcantly lower in the TSOD-WTD
group than in the TSOD-MF group but the energy intake
was not diﬀerent. On the other hand, the food and energy
intake were not diﬀerent between the TSOD-WTD group
and the TSOD-WTD-Flavangenol groups. The data on food
and energy intake obtained at 2, 4 and 6 weeks after the start
of the experiment in each group were almost the same as the
data obtained after 8 weeks.
3.2. Accumulation of Visceral and Subcutaneous Fat.
Figure 2(a) is a CT image from around the sixth lumbar
vertebra of a representative mouse showing the average body
weight of each group determined 8 weeks after the start of
the experiment. The abdominal circumference increased
more in the TSOD-MF group than in the TSNO-MF group
and further increased markedly in the TSOD-WTD group.
On the other hand, in groups treated with Flavangenol,
the extreme increase in abdominal circumference seen in
the TSOD-WTD group was prevented. The amount of
visceral and subcutaneous fat was signiﬁcantly higher in
the TSOD-MF group than in the TSNO-MF group and
further markedly higher in the TSOD-WTD group fed
with WTD (Figure 2(b)). Both the accumulated visceral and
subcutaneousfatamountsshowedsigniﬁcantlyhighervalues
from 4 weeks after the start of the experiment. On the other
hand, in the TSOD-WTD-Flavangenol groups, a signiﬁcant
suppressive eﬀect on accumulation of both visceral and
subcutaneous fat was seen from 4 weeks after the start of
the experiment in comparison with the TSOD-WTD group,
and the amounts of visceral and subcutaneous fat in the
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Figure 1: The eﬀect of Flavangenol on body weight in mice. Closed
diamond: TSNO-MF; closed square: TSOD-MF; closed triangle:
TSOD-WTD; open square: TSOD-WTD-Flavangenol 3%; open
triangle: TSOD-WTD-Flavangenol 5%. Data represent the mean
± SD of 8-9 animals. ∗∗P < .01, signiﬁcant diﬀerences from the
TSOD-MF group. ##P < .05 and .01, signiﬁcant diﬀerences from the
TSOD-WTD group.
TSOD-WTD-Flavangenol groups became lower than in the
TSOD-MF group.
3.3. Tissue Weights and Autopsy. On comparing the TSNO-
MF and the TSOD-MF groups, no signiﬁcant diﬀerence was
seen in liver weight, and no particular diﬀerences were seen
in liver autopsy ﬁndings either. Between the TSOD-MF and
the TSOD-WTD groups, a signiﬁcant increase in liver weight
due to the WTD was conﬁrmed, and the autopsy ﬁndings
also conﬁrmed the marked liver enlargement and fatty liver.
On the other hand, the liver enlargement and fatty liver
seen in the TSOD-WTD group were markedly prevented by
administration of Flavangenol (Figure 3 and Table 2).
The epididymal and retroperitoneal fat accumulated
about 5 and 3.5 times more, respectively, in the TSOD-MF
group as compared with the TSNO-MF group, but there
were no signiﬁcant diﬀerences between the TSOD-MF and
the TSOD-WTD groups. Mesenteric and perinephric fat
also accumulated about 4.5 and 7 times more, respectively,
in the TSOD-MF group as compared with the TSNO-MF
group and accumulated further in the TSOD-WTD group.
Administration of Flavangenol signiﬁcantly suppressed fat
accumulation in each visceral adipose tissue, and the
amounts of mesenteric fat and perinephric fat were lower
by50 and60%,respectively,intheTSOD-WTD-Flavangenol
5% group than in the TSOD-WTD group, and the amounts
of epididymal fat and retroperitoneal fat were lower by 10
and 30%, respectively.
3.4. Biochemical Test Values. Table 3 shows the biochemical
test values of the plasma samples obtained in each group 8
weeks after the start of the experiment.
The non-fasting blood glucose level was not diﬀerent
between the TSNO-MF and TSOD-MF groups, but a
signiﬁcant increase was seen due to provision of the WTD
in TSOD group. When Flavangenol was administered, the
non-fasting blood glucose level was signiﬁcantly lower in4 Evidence-Based Complementary and Alternative Medicine
Table 1: The eﬀects of Flavangenol on food intake and energy intake at 8 weeks treatment.
TSNO MF TSOD
MF WTD WTD-ﬂavangenol 3% WTD-ﬂavangenol 5%
Food intake (g/day/body) 4.5 ± 0.3∗ 5.2 ± 0.3 4.3 ± 0.0∗∗ 4.0 ± 0.2 4.3 ± 0.4
Energy intake (kcal/day/body) 16.2 ± 1.1∗ 18.6 ± 0.9 19.6 ± 0.2 19.4 ± 1.9 19.2 ± 1.7
Data represent the mean ± SD of 8-9 animals.
∗P < .05 and ∗∗P < .01 Signiﬁcant diﬀerences from the TSOD-MF group.
Table 2: The eﬀects of Flavangenol on liver and visceral fat weight for each viscus.
TSNO-MF TSOD
MF WTD WTD-ﬂavangenol 3% WTD-ﬂavangenol 5%
Liver (g) 1.69 ± 0.19 1.89 ± 0.17 3.03 ± 0.64∗∗ 1.79 ± 0.11## 1.79 ± 0.10##
Epididymal fat (g) 0.59 ± 0.15∗ 2.92 ± 0.27 3.09 ± 0.23 3.11 ± 0.33 2.77 ± 0.29#
Mesenteric fat (g) 0.35 ± 0.I6∗∗ 1.60 ± 0.39 2.02 ± 0.28∗ 1.21 ± 0.27## 1.04 ± 0.36##
Retroperitoneal fat (g) 0.17 ± 0.05∗∗ 0.65 ± 0.09 0.78 ± 0.20 0.56 ± 0.05## 0.57 ± 0.07##
Perinephric fat (g) 0.08 ± 0.02∗∗ 0.59 ± 0.13 0.94 ± 0.13∗∗ 0.41 ± 0.11## 0.35 ± 0.12##
Data represent the mean ± SD of 8-9 animals. ∗P < .05 and ∗∗P < .01 Signiﬁcant diﬀerences from the TSOD MF group. #P < .05 and ##P < .01 Signiﬁcant
diﬀerences from the TSOD-WTD group.
a dose-dependent manner as compared with the TSOD-
WTDgroup.Thefastingbloodglucoselevelwassigniﬁcantly
higher in the TSOD-MF group than in the TSNO-MF group
and even higher in the TSOD-WTD group, but this increase
was suppressed in the TSOD-WTD-Flavangenol groups in
a dose-dependent manner. The total cholesterol level was
signiﬁcantly higher in the TSOD-MF group than in the
TSNO-MF group and further higher in the TSOD-WTD
group, but there were no signiﬁcant diﬀerences between the
TSOD-WTD group and TSOD-WTD-Flavangenol groups.
The triacylglycerol level and free fatty acid level were signif-
icantly higher in the TSOD-MF group than in the TSNO-
MF group, but no signiﬁcant diﬀerences were seen between
the TSOD-MF and the TSOD-WTD groups or TSOD-
WTD-Flavangenol groups. The insulin level was signiﬁcantly
higher in the TSOD-MF group than in the TSNO-MF
group and even higher in the TSOD-WTD group, but this
increase was suppressed in the TSOD-WTD-Flavangenol
groups in a dose-dependent manner. The adiponectin level
was signiﬁcantly lower in the TSOD-MF group than in
the TSNO-MF group and still lower in the TSOD-WTD
group, but this decrease was suppressed in the TSOD-WTD-
Flavangenol groups in a dose-dependent manner. The TNF-
α level was signiﬁcantly higher in the TSOD-MF group
than in the TSNO-MF group, but there were no signiﬁcant
diﬀerences between the TSOD-MF group and the TSOD-
WTD group, and this increase was signiﬁcantly suppressed
in the TSOD-WTD-Flavangenol 5% group.
3.5. Glucose-Loading Test and Blood Pressure Determination.
The blood glucose level was higher in the TSOD-MF group
than in the TSNO-MF group at all times determined, and
was even higher in the TSOD-WTD group than in the
TSOD-MF group at 0.5 and 1h after loading; postpran-
dial hyperglycemia was seen in the TSOD-WTD group
(Figure 4). Conversely, in the Flavangenol-treated groups,
dose-dependent suppression was seen as compared with the
TSOD-WTD group, and signiﬁcant suppression was seen at
0.5, 1 and 2h after loading in the TSOD-WTD-Flavangenol
5% group.
The diastolic blood pressure and mean blood pressure
were signiﬁcantly higher in the TSOD-MF group than
in the TSNO-MF group, and the hypertensive ﬁndings
were conﬁrmed in the TSOD-MF group (Figure 5). A
comparison between the TSOD-MF and the TSOD-WTD
groups revealed that the blood pressure tended to be higher
in the latter. In spite of the increased blood pressure in
the TSOD-WTD group, diastolic blood pressure and mean
blood pressure were signiﬁcantly lower in the TSOD-WTD-
Flavangenol 5% group.
3.6. Olive-Oil-Loading Test and Pancreatic Lipase Inhibition
Test. In the olive-oil-loading test, the plasma triacylglycerol
level after loading with olive oil increased, showing a peak
value at 2h after loading, but this increase was inhibited by
pretreatment with Flavangenol in a dose-dependent man-
ner. Flavangenol (1.0g/kg) administered orally signiﬁcantly
suppressed the plasma triacylglycerol level at 1, 2 and 4h
afteradministration(Figure 6).Inaddition,inthepancreatic
lipase inhibition test, Flavangenol showed an inhibitory
eﬀect on pancreatic lipase activity, with an IC50 value of
335μg/mL.
4. Discussion
Variousmetabolicdiseasesbasedonaccumulationofvisceral
fat are known to become serious when some environmental
factor is added [22, 23]. In this study, the preventive eﬀect
of Flavangenol on metabolic diseases was investigated by
using a model that mimicked the modern human metabolic
diseases by providing a WTD to TSOD mice, a sponta-
neous obese mouse model of type II diabetes. Additionally,Evidence-Based Complementary and Alternative Medicine 5
Table 3: The eﬀects of Flavangenol on biochemical parameters of plasma.
TSNO-MF TSOD
MF WTD WTD-ﬂavangenol 3% WTD-ﬂavangenol 5%
Non-fasted glucose (mg/dL) 169.1 ± 20.7 172.0 ± 22.3 330.0 ± 126.7∗∗ 178.4 ± 32.8## 168.2 ± 17.0##
Fast glucose (mg/dL) 120.0 ± 23.8∗ 168.2 ± 35.6 228.4 ± 42.6∗∗ 172.8 ± 42.7# 163.2 ± 44.0##
Total cholesterol (mg/dL) 113.9 ± 12.4∗∗ 170.1 ± 27.7 260.1 ± 27.0∗∗ 255.9 ± 31.8 247.0 ± 21.6
Triacylglycerol (mg/dL) 118.9 ± 32.0∗∗ 198.3 ± 38.2 239.4 ± 52.2 231.7 ± 50.6 261.7 ± 59.4
Free fat acid (mEq/l) 1.17 ± 0.14∗∗ 1.46 ± 0.27 1.69 ± 0.27 1.68 ± 0.35 1.70 ± 0.16
Insulin (ng/mL) 2.8 ± 1.3 15.4 ± 14.3 143.0 ± 81.4∗∗ 36.2 ± 62.9## 10.3 ± 13.6##
Adiponectin (μg/mL) 5.20 ± 0.71∗∗ 2.71 ± 0.51 1.75 ± 0.29∗∗ 2.23 ± 0.36## 2.41 ± 0.34##
TNF-α (pg/mL) 4.7 ± 0.3∗∗ 11.1 ± 3.1 10.4 ± 3.9 10.0 ± 2.1 7.2 ± 1.3##
Data represent the mean ± SD of 8-9 animals. ∗P < .05 and ∗∗P < .01 Signiﬁcant diﬀerences from the TSOD-MF group. #P<.05 and ##P < .01 Signiﬁcant
diﬀerences from the TSOD-WTD group.
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Figure 2: The eﬀect of Flavangenol on the accumulation of adipose tissue in mice. (A) X-ray CT images of subcutaneous and visceral fat
at 12 weeks. The yellow color shows the subcutaneous fat and the deep pink color shows the visceral fat. (a)TSNO-MF; (b)TSOD-MF;
(c) TSOD-WTD; (d) TSOD-WTD-Flavangenol 3%; (e): TSOD-WTD-Flavangenol 5%. (B) Time-course of subcutaneous and visceral fat
accumulation. closed diamond: TSNO-MF; closed square: TSOD-MF; closed triangle: TSOD-WTD; open square: TSOD-WTD-Flavangenol
3%; open triangle: TSOD-WTD-Flavangenol 5%. Data represent the mean ± SD of 8-9 animals. ∗∗P < .01, signiﬁcant diﬀerences from the
TSOD-MF group; ##P < .01, signiﬁcant diﬀerences from the TSOD-WTD group.
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Figure 3: The eﬀect of Flavangenol on the liver texture. (a) TSNO-MF; (b) TSOD-MF; (c) TSOD-WTD; (d) TSOD-WTD-Flavangenol 3%;
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Figure 4: The eﬀect of Flavangenol on the plasma glucose level
in the oral glucose tolerance test. Closed diamond: TSNO-MF;
closed square: TSOD-MF; closed triangle: TSOD-WTD; open
square: TSOD-WTD-Flavangenol 3%; open triangle: TSOD-WTD-
Flavangenol 5%. Data represent the mean ± SD of 8-9 animals. ∗∗P
< .01, signiﬁcant diﬀerences from the TSOD-MF group. ##P < .01,
signiﬁcant diﬀerences from the TSOD-WTD group.
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Figure 5: The eﬀect of Flavangenol on blood pressure. Data repre-
sent the mean ±SD of 8-9 animals. ∗P < .05, signiﬁcant diﬀerences
fromtheTSOD-MFgroup; #P <.05,signiﬁcantdiﬀerencesfromthe
TSOD-WTD group.
for the purpose of clarifying the action mechanism of
Flavangenol, we investigated the eﬀect of Flavangenol on
absorption of meal-derived lipids.
As reported previously, the TSOD-MF group showed
increased food intake, obesity with predominant accumu-
lation of visceral fat, insulin resistance and other metabolic
complications, as compared with the TSNO-MF group
[17–20]. When TSOD mice were given a WTD as an
environmental factor, further signiﬁcant obesity was seen
from about 2 weeks after the start of the treatment, and
signiﬁcantaccumulationofvisceralfat(especiallymesenteric
fat and perinephric fat) and subcutaneous fat, marked
liver enlargement and fatty liver were observed. On blood
biochemical tests, signiﬁcant increases of fasting/non-fasting
blood glucose levels, total cholesterol and insulin levels and
a signiﬁcant decrease in adiponectin level were conﬁrmed.
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Figure 6: The eﬀect of Flavangenol on plasma triacylglycerol
elevation in olive-oil-loaded ddY mice Closed diamond: Normal
(water); open triangle: Flavangenol 0.5g/kg p.o.; open square:
Flavangenol 1.0g/kg p.o. Data represent the mean ±SD of six
animals. ∗P < .05 and ∗∗P < .01, signiﬁcant diﬀerences from the
normal mice.
It was clariﬁed that more severe metabolic diseases appeared
in the TSOD-WTD group following administration of a
WTD as an environmental factor, as these mice have genes
for metabolic disease. In the present study, the food intake
was signiﬁcantly lower in the TSOD-WTD group, but the
converted energy intake was not lower.
The eﬀect of Flavangenol added to the diet of the TSOD-
WTD group was marked. Flavangenol did not inﬂuence
the food and energy intake but, in a dose-dependent
manner, suppressed the body weight increase due to a
WTD. In the adipose tissues, which are closely related to an
increase/decreaseinbodyweight,itwasclariﬁedbyX-rayCT
analysis that Flavangenol showed a signiﬁcant suppressive
eﬀect on accumulation of visceral and subcutaneous fat in
a time-course manner. Looking at the suppressive eﬀect
on fat accumulation by visceral adipose tissue, a stronger
eﬀect was observed on mesenteric and perinephric fat,
which increased more signiﬁcantly on the WTD. When we
previously investigated the eﬀect of Flavangenol in a model
developed by giving a high-fat diet to Sprague Dawley (SD)
rats, we observed a signiﬁcant suppressive eﬀect on increase
in body weight, accumulation of visceral fat and an increase
in fecal excretion of total lipid in the group given a diet
containing 2% Flavangenol (unpublished results). In the
present study, similar results were obtained in the severe
disease state that mimicked human disease by combining
genetic and environmental factors. Additionally, it was also
clariﬁed that Flavangenol showed a preventive eﬀect on liver
enlargement and fatty liver. Recently, it has been strongly
suggested that fatty liver is involved in onset and progression
of non-alcoholic steatohepatitis (NASH) [24]. It is therefore
anticipated that Flavangenol may also exert a preventive
eﬀect against NASH.
It was reported that visceral fat accumulation or
adipocyte hypertrophy induces insulin resistance and the
mechanism of action involves decreased secretion of
adiponectin (which is known to improve arteriosclerosis
and various metabolic diseases) and increased secretionEvidence-Based Complementary and Alternative Medicine 7
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Figure 7: Mechanisms of action of anti-metabolic disease by Flavangenol.
of TNFα (which induces insulin resistance) [25]. In this
study, Flavangenol signiﬁcantly suppressed accumulation of
visceral fat, signiﬁcantly prevented the hyperglycemia and
hyperinsulinemia observed in the TSOD-WTD group and
prevented onset of abnormal glucose tolerance, suggesting
a role in improved insulin resistance. In addition, since
Flavangenol signiﬁcantly increased the adiponectin level and
signiﬁcantly decreased the TNF-α level, it is suggested that
the abnormal secretion of adipocytokines was normalized
and onset of insulin resistance was prevented as a result,
by the suppressive eﬀect of Flavangenol on hypertrophy and
accumulation of adipocytes. In this study, the body weight,
amounts of visceral and subcutaneous fat and liver weight
were lower in the TSOD-WTD-Flavangenol groups than
in the TSOD-MF group. Furthermore, the plasma TNFα
level was signiﬁcantly lowered by Flavangenol, though not
inﬂuenced by providing a WTD, suggesting that Flavangenol
was eﬀective not only for the obesity induced by a WTD but
also on the original hereditary obesity of TSOD mice.
In this study, Flavangenol did not show a suppressive
eﬀect on the increases in blood levels of lipids, such as
total cholesterol, triacylglycerol and free fatty acid levels,
observed in the TSOD-WTD group. On the other hand, Fla-
vangenol signiﬁcantly suppressed accumulation of visceral
andsubcutaneousfatandonsetoffattyliver.Mochizukietal.
[26] reported that Pine bark extract enhanced lipolysis by
stimulation of β-receptors in a study using 3T3 cells. It
is suggested that enhancement of lipolysis by Flavangenol
through stimulation of β-receptors might be involved in
the preventive eﬀect of Flavangenol on onset of fatty liver
and fat accumulation. Conversely, it is also suggested that a
suppressiveeﬀectofFlavangenolonincreasedplasmatriacyl-
glycerolandfreefattyacidlevelswasnotseen,duetotransfer
to plasma of free fatty acids formed through lipid decom-
position in the liver and adipocytes. It is known that fat
accumulation in the liver and skeletal muscles or abnormal
secretion of adipocytokines from hypertrophic adipocytes
induces onset of insulin resistance. It is considered impor-
tant that onset of fatty liver and fat accumulation was
prevented by Flavangenol in this study, though Flavangenol
did not show a preventive eﬀect on increases in blood lipid
levels.8 Evidence-Based Complementary and Alternative Medicine
Hypertension is one of the diagnostic criteria for the
metabolic syndrome, and Flavangenol showed a signiﬁcant
antihypertensive eﬀect (on diastolic and mean blood
pressure). Pine bark extract was reported to show vascular
protection due to an antioxidant eﬀect [6], endothelium-
dependent vasodilatation [27], improvement of endothelial
cell function in hypertension patients [5] and activation of
endothelial nitric oxide synthase (eNOS) in the endothelial
cells [6]. Also, it is suggested that the suppressive eﬀect of
Flavangenol on hypertension seen in this study involves a
direct eﬀect on the endothelial cells and an indirect eﬀect
through suppression of the onset of insulin resistance.
In this study, more severe features of metabolic disease
appeared in the TSOD-WTD group following administra-
tion of a WTD as an environmental factor to TSOD mice
that had metabolic disease genes as a genetic factor. It
was therefore suggested that the increased absorption of
meal-derived lipids was involved in aggravation of various
metabolic disease symptoms. It was reported that plant-
derived polyphenols suppress absorption of triacylglycerol
and cholesterol [28–30], suggesting that the eﬀect of Fla-
vangenol on prevention of metabolic disease observed in
this study involves a lipid-absorption-inhibiting eﬀect. In the
in vivo experiment using ddY mice, Flavangenol showed a
signiﬁcant, dose-dependent suppressive eﬀect on absorption
of triacylglycerol. In addition, in the in vitro experiment,
Flavangenol was conﬁrmed to have an inhibitory eﬀect on
pancreatic lipase, which is the rate-determining enzyme
involved in absorption of meal-derived triacylglycerol (IC50
value: 335μgmL −1). This eﬀect was at the same level as
the eﬀects of tea catechins and heat-treated tea catechins,
which are known to have an inhibitory eﬀect on lipid
absorption [31]. Apple-derived oligomeric procyanidins
were reported to have a lipase-inhibiting eﬀect and show an
inhibitory eﬀect on lipid absorption in mice and humans
[32], supporting the results obtained in this study. The fact
that Flavangenol increased fecal excretion of total lipid in
the SD rats loaded with a high-fat diet (to be submitted)
endorses the results obtained in this study. In addition,
Pine bark extract was reported to inhibit also α-Glucosidase
involved in absorption of meal-derived sugars [33]. It is
thus suggested that the mechanisms of the hypoglycemic
eﬀectandmetabolic-disease-preventingeﬀectofFlavangenol
observed in this study might have included the inhibitory
eﬀect on absorption of meal-derived lipids and sugars
(Figure 7). However, inhibitory activity on the enzyme is
unlikely the main underlying mechanism.
Although our ﬁndings suggest beneﬁcial metabolic
eﬀects of Flavangenol in a genetic animal model of type 2
diabetes and obesity, the endogenous mechanisms need to
be further investigated in future.
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